nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—Gefitinib—Lapatinib—breast cancer	0.398	1	CrCrCtD
Iloperidone—CYP2D6—breast cancer	0.0658	0.538	CbGaD
Iloperidone—CYP3A4—breast cancer	0.0565	0.462	CbGaD
Iloperidone—SIGMAR1—Raloxifene—breast cancer	0.0405	0.133	CbGbCtD
Iloperidone—HTR6—Raloxifene—breast cancer	0.0304	0.0994	CbGbCtD
Iloperidone—SIGMAR1—Tamoxifen—breast cancer	0.0268	0.0876	CbGbCtD
Iloperidone—CYP1A2—Anastrozole—breast cancer	0.0127	0.0416	CbGbCtD
Iloperidone—CYP1A2—Toremifene—breast cancer	0.0116	0.038	CbGbCtD
Iloperidone—CYP3A5—Lapatinib—breast cancer	0.0114	0.0373	CbGbCtD
Iloperidone—CYP3A4—Exemestane—breast cancer	0.00878	0.0287	CbGbCtD
Iloperidone—CYP2D6—Idarubicin—breast cancer	0.00793	0.026	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0076	0.0249	CbGbCtD
Iloperidone—CYP3A7—Tamoxifen—breast cancer	0.0076	0.0249	CbGbCtD
Iloperidone—CYP3A4—Letrozole—breast cancer	0.00747	0.0244	CbGbCtD
Iloperidone—CYP2E1—Tamoxifen—breast cancer	0.00734	0.024	CbGbCtD
Iloperidone—CYP2E1—Mitoxantrone—breast cancer	0.00716	0.0234	CbGbCtD
Iloperidone—CYP3A4—Anastrozole—breast cancer	0.00666	0.0218	CbGbCtD
Iloperidone—CYP3A4—Toremifene—breast cancer	0.00609	0.0199	CbGbCtD
Iloperidone—CYP3A7—Paclitaxel—breast cancer	0.00592	0.0194	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00592	0.0194	CbGbCtD
Iloperidone—CYP3A7—Irinotecan—breast cancer	0.00584	0.0191	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00584	0.0191	CbGbCtD
Iloperidone—CYP3A5—Tamoxifen—breast cancer	0.0057	0.0187	CbGbCtD
Iloperidone—CYP3A4—Fulvestrant—breast cancer	0.00566	0.0185	CbGbCtD
Iloperidone—CYP3A4—Thiotepa—breast cancer	0.00505	0.0165	CbGbCtD
Iloperidone—CYP3A4—Ixabepilone—breast cancer	0.00461	0.0151	CbGbCtD
Iloperidone—CYP3A4—Lapatinib—breast cancer	0.00444	0.0145	CbGbCtD
Iloperidone—CYP3A5—Paclitaxel—breast cancer	0.00444	0.0145	CbGbCtD
Iloperidone—CYP3A5—Irinotecan—breast cancer	0.00438	0.0143	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00428	0.014	CbGbCtD
Iloperidone—CYP3A7—Docetaxel—breast cancer	0.00428	0.014	CbGbCtD
Iloperidone—CYP1A2—Tamoxifen—breast cancer	0.00425	0.0139	CbGbCtD
Iloperidone—CYP2D6—Vinorelbine—breast cancer	0.00387	0.0127	CbGbCtD
Iloperidone—CYP2D6—Tamoxifen—breast cancer	0.0035	0.0114	CbGbCtD
Iloperidone—CYP3A4—Raloxifene—breast cancer	0.00337	0.011	CbGbCtD
Iloperidone—CYP3A5—Docetaxel—breast cancer	0.00321	0.0105	CbGbCtD
Iloperidone—CYP1A2—Fluorouracil—breast cancer	0.00313	0.0102	CbGbCtD
Iloperidone—CYP3A4—Vinorelbine—breast cancer	0.00246	0.00806	CbGbCtD
Iloperidone—CYP2D6—Vinblastine—breast cancer	0.00239	0.00781	CbGbCtD
Iloperidone—CYP3A4—Tamoxifen—breast cancer	0.00222	0.00728	CbGbCtD
Iloperidone—CYP3A4—Mitoxantrone—breast cancer	0.00217	0.0071	CbGbCtD
Iloperidone—CYP3A4—Paclitaxel—breast cancer	0.00173	0.00566	CbGbCtD
Iloperidone—CYP3A4—Irinotecan—breast cancer	0.00171	0.00559	CbGbCtD
Iloperidone—CYP3A4—Vinblastine—breast cancer	0.00152	0.00497	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—breast cancer	0.00147	0.0048	CbGbCtD
Iloperidone—CYP3A4—Docetaxel—breast cancer	0.00125	0.00409	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—breast cancer	0.000933	0.00305	CbGbCtD
Iloperidone—Gefitinib—CHEK2—breast cancer	0.000514	0.195	CrCbGaD
Iloperidone—Gefitinib—ERBB3—breast cancer	0.000458	0.174	CrCbGaD
Iloperidone—SIGMAR1—mammary gland—breast cancer	0.000364	0.0417	CbGeAlD
Iloperidone—SIGMAR1—nipple—breast cancer	0.000301	0.0345	CbGeAlD
Iloperidone—CYP3A7—endocrine gland—breast cancer	0.000238	0.0273	CbGeAlD
Iloperidone—ADRA2C—nipple—breast cancer	0.000236	0.0271	CbGeAlD
Iloperidone—Gefitinib—EGFR—breast cancer	0.000206	0.0779	CrCbGaD
Iloperidone—CYP1A2—nipple—breast cancer	0.000205	0.0235	CbGeAlD
Iloperidone—HRH1—nipple—breast cancer	0.000192	0.022	CbGeAlD
Iloperidone—ADRA2A—nipple—breast cancer	0.000189	0.0216	CbGeAlD
Iloperidone—SIGMAR1—endometrium—breast cancer	0.000182	0.0208	CbGeAlD
Iloperidone—Paliperidone—CYP2D6—breast cancer	0.000174	0.0659	CrCbGaD
Iloperidone—HTR7—epithelium—breast cancer	0.000173	0.0198	CbGeAlD
Iloperidone—SIGMAR1—uterus—breast cancer	0.000167	0.0192	CbGeAlD
Iloperidone—ADRA1A—epithelium—breast cancer	0.000167	0.0191	CbGeAlD
Iloperidone—SIGMAR1—pituitary gland—breast cancer	0.000164	0.0188	CbGeAlD
Iloperidone—SIGMAR1—adipose tissue—breast cancer	0.000164	0.0188	CbGeAlD
Iloperidone—HTR1D—female reproductive system—breast cancer	0.000161	0.0185	CbGeAlD
Iloperidone—HTR2C—female reproductive system—breast cancer	0.00016	0.0183	CbGeAlD
Iloperidone—Gefitinib—ABCG2—breast cancer	0.00015	0.0569	CrCbGaD
Iloperidone—Paliperidone—CYP3A4—breast cancer	0.000149	0.0565	CrCbGaD
Iloperidone—SIGMAR1—adrenal gland—breast cancer	0.000147	0.0168	CbGeAlD
Iloperidone—ADRA2C—endometrium—breast cancer	0.000143	0.0164	CbGeAlD
Iloperidone—SIGMAR1—bone marrow—breast cancer	0.000142	0.0163	CbGeAlD
Iloperidone—SIGMAR1—female gonad—breast cancer	0.000137	0.0157	CbGeAlD
Iloperidone—ADRA1A—adipose tissue—breast cancer	0.000135	0.0155	CbGeAlD
Iloperidone—DRD2—pituitary gland—breast cancer	0.000133	0.0152	CbGeAlD
Iloperidone—HTR2A—embryo—breast cancer	0.000132	0.0152	CbGeAlD
Iloperidone—Cisapride—CYP2D6—breast cancer	0.000132	0.0499	CrCbGaD
Iloperidone—ADRA2C—uterus—breast cancer	0.000131	0.0151	CbGeAlD
Iloperidone—HTR1A—adrenal gland—breast cancer	0.000131	0.0151	CbGeAlD
Iloperidone—Risperidone—CYP2D6—breast cancer	0.00013	0.0491	CrCbGaD
Iloperidone—HRH1—epithelium—breast cancer	0.000129	0.0148	CbGeAlD
Iloperidone—ADRA2C—pituitary gland—breast cancer	0.000129	0.0148	CbGeAlD
Iloperidone—HTR7—female reproductive system—breast cancer	0.000129	0.0147	CbGeAlD
Iloperidone—ADRA2C—adipose tissue—breast cancer	0.000129	0.0147	CbGeAlD
Iloperidone—HTR7—adrenal gland—breast cancer	0.000125	0.0144	CbGeAlD
Iloperidone—ADRA1A—adrenal gland—breast cancer	0.000121	0.0139	CbGeAlD
Iloperidone—Gefitinib—CYP1A1—breast cancer	0.000118	0.0446	CrCbGaD
Iloperidone—HRH1—endometrium—breast cancer	0.000116	0.0133	CbGeAlD
Iloperidone—ADRA2C—adrenal gland—breast cancer	0.000115	0.0132	CbGeAlD
Iloperidone—HTR1A—endocrine gland—breast cancer	0.000114	0.0131	CbGeAlD
Iloperidone—ADRA2A—endometrium—breast cancer	0.000114	0.0131	CbGeAlD
Iloperidone—Cisapride—CYP3A4—breast cancer	0.000113	0.0428	CrCbGaD
Iloperidone—Risperidone—CYP3A4—breast cancer	0.000111	0.0421	CrCbGaD
Iloperidone—HTR7—endocrine gland—breast cancer	0.000109	0.0125	CbGeAlD
Iloperidone—HTR2A—epithelium—breast cancer	0.000108	0.0124	CbGeAlD
Iloperidone—CYP3A5—adipose tissue—breast cancer	0.000108	0.0123	CbGeAlD
Iloperidone—ADRA2C—female gonad—breast cancer	0.000108	0.0123	CbGeAlD
Iloperidone—ADRA1A—endocrine gland—breast cancer	0.000105	0.012	CbGeAlD
Iloperidone—ADRA2A—uterus—breast cancer	0.000105	0.012	CbGeAlD
Iloperidone—HRH1—adipose tissue—breast cancer	0.000104	0.012	CbGeAlD
Iloperidone—ADRA2A—pituitary gland—breast cancer	0.000103	0.0118	CbGeAlD
Iloperidone—DRD2—endocrine gland—breast cancer	0.000103	0.0118	CbGeAlD
Iloperidone—ADRA2A—adipose tissue—breast cancer	0.000103	0.0118	CbGeAlD
Iloperidone—HRH1—female reproductive system—breast cancer	9.6e-05	0.011	CbGeAlD
Iloperidone—ADRA2A—female reproductive system—breast cancer	9.43e-05	0.0108	CbGeAlD
Iloperidone—HRH1—adrenal gland—breast cancer	9.37e-05	0.0107	CbGeAlD
Iloperidone—Risperidone—ABCB1—breast cancer	9.25e-05	0.0351	CrCbGaD
Iloperidone—CYP2E1—female reproductive system—breast cancer	9.22e-05	0.0106	CbGeAlD
Iloperidone—ADRA2A—adrenal gland—breast cancer	9.2e-05	0.0106	CbGeAlD
Iloperidone—CYP2E1—adrenal gland—breast cancer	9e-05	0.0103	CbGeAlD
Iloperidone—CYP3A5—female gonad—breast cancer	9e-05	0.0103	CbGeAlD
Iloperidone—SIGMAR1—lymph node—breast cancer	8.8e-05	0.0101	CbGeAlD
Iloperidone—HTR2A—pituitary gland—breast cancer	8.76e-05	0.01	CbGeAlD
Iloperidone—Gefitinib—CYP2D6—breast cancer	8.75e-05	0.0332	CrCbGaD
Iloperidone—HRH1—female gonad—breast cancer	8.73e-05	0.01	CbGeAlD
Iloperidone—CYP1A2—endocrine gland—breast cancer	8.68e-05	0.00995	CbGeAlD
Iloperidone—ADRA2A—female gonad—breast cancer	8.58e-05	0.00984	CbGeAlD
Iloperidone—CYP3A5—endocrine gland—breast cancer	8.37e-05	0.0096	CbGeAlD
Iloperidone—HRH1—endocrine gland—breast cancer	8.12e-05	0.00931	CbGeAlD
Iloperidone—HTR2A—female reproductive system—breast cancer	8.02e-05	0.00919	CbGeAlD
Iloperidone—ADRA2A—endocrine gland—breast cancer	7.98e-05	0.00915	CbGeAlD
Iloperidone—HTR2A—adrenal gland—breast cancer	7.82e-05	0.00897	CbGeAlD
Iloperidone—CYP2E1—endocrine gland—breast cancer	7.81e-05	0.00895	CbGeAlD
Iloperidone—Gefitinib—CYP3A4—breast cancer	7.51e-05	0.0285	CrCbGaD
Iloperidone—CYP3A4—female reproductive system—breast cancer	7.42e-05	0.00851	CbGeAlD
Iloperidone—CYP2D6—female reproductive system—breast cancer	7.3e-05	0.00837	CbGeAlD
Iloperidone—ADRA2C—lymph node—breast cancer	6.91e-05	0.00793	CbGeAlD
Iloperidone—HTR2A—endocrine gland—breast cancer	6.78e-05	0.00778	CbGeAlD
Iloperidone—CYP2D6—female gonad—breast cancer	6.65e-05	0.00762	CbGeAlD
Iloperidone—Gefitinib—ALB—breast cancer	6.55e-05	0.0248	CrCbGaD
Iloperidone—CYP3A4—endocrine gland—breast cancer	6.28e-05	0.0072	CbGeAlD
Iloperidone—Gefitinib—ABCB1—breast cancer	6.25e-05	0.0237	CrCbGaD
Iloperidone—CYP2D6—endocrine gland—breast cancer	6.18e-05	0.00709	CbGeAlD
Iloperidone—HRH1—lymph node—breast cancer	5.62e-05	0.00644	CbGeAlD
Iloperidone—ADRA2A—lymph node—breast cancer	5.52e-05	0.00632	CbGeAlD
Iloperidone—Dizziness—Vinorelbine—breast cancer	4.22e-05	0.000414	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—breast cancer	4.22e-05	0.000414	CcSEcCtD
Iloperidone—Nervous system disorder—Paclitaxel—breast cancer	4.21e-05	0.000413	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—breast cancer	4.2e-05	0.000413	CcSEcCtD
Iloperidone—Tachycardia—Paclitaxel—breast cancer	4.19e-05	0.000411	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—breast cancer	4.17e-05	0.00041	CcSEcCtD
Iloperidone—Diarrhoea—Thiotepa—breast cancer	4.17e-05	0.000409	CcSEcCtD
Iloperidone—Body temperature increased—Irinotecan—breast cancer	4.16e-05	0.000408	CcSEcCtD
Iloperidone—Body temperature increased—Mitoxantrone—breast cancer	4.16e-05	0.000408	CcSEcCtD
Iloperidone—Feeling abnormal—Fluorouracil—breast cancer	4.15e-05	0.000408	CcSEcCtD
Iloperidone—Muscle spasms—Capecitabine—breast cancer	4.15e-05	0.000407	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—breast cancer	4.13e-05	0.000405	CcSEcCtD
Iloperidone—Anaemia—Docetaxel—breast cancer	4.12e-05	0.000404	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—breast cancer	4.09e-05	0.000401	CcSEcCtD
Iloperidone—Vision blurred—Capecitabine—breast cancer	4.07e-05	0.000399	CcSEcCtD
Iloperidone—Body temperature increased—Gemcitabine—breast cancer	4.05e-05	0.000398	CcSEcCtD
Iloperidone—Tremor—Capecitabine—breast cancer	4.04e-05	0.000397	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—breast cancer	4.03e-05	0.000396	CcSEcCtD
Iloperidone—Dizziness—Thiotepa—breast cancer	4.03e-05	0.000396	CcSEcCtD
Iloperidone—Rash—Vinorelbine—breast cancer	4.02e-05	0.000395	CcSEcCtD
Iloperidone—Dermatitis—Vinorelbine—breast cancer	4.02e-05	0.000395	CcSEcCtD
Iloperidone—Hypotension—Paclitaxel—breast cancer	4.01e-05	0.000394	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—breast cancer	4.01e-05	0.000394	CcSEcCtD
Iloperidone—Stomatitis—Methotrexate—breast cancer	4.01e-05	0.000393	CcSEcCtD
Iloperidone—Conjunctivitis—Methotrexate—breast cancer	3.99e-05	0.000392	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—breast cancer	3.99e-05	0.000392	CcSEcCtD
Iloperidone—Leukopenia—Docetaxel—breast cancer	3.99e-05	0.000392	CcSEcCtD
Iloperidone—Anaemia—Capecitabine—breast cancer	3.99e-05	0.000392	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—breast cancer	3.98e-05	0.000391	CcSEcCtD
Iloperidone—Body temperature increased—Fluorouracil—breast cancer	3.98e-05	0.000391	CcSEcCtD
Iloperidone—Palpitations—Docetaxel—breast cancer	3.94e-05	0.000387	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—breast cancer	3.92e-05	0.000385	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Paclitaxel—breast cancer	3.91e-05	0.000384	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—breast cancer	3.9e-05	0.000383	CcSEcCtD
Iloperidone—Hepatobiliary disease—Methotrexate—breast cancer	3.89e-05	0.000382	CcSEcCtD
Iloperidone—Epistaxis—Methotrexate—breast cancer	3.88e-05	0.000381	CcSEcCtD
Iloperidone—Vertigo—Capecitabine—breast cancer	3.88e-05	0.000381	CcSEcCtD
Iloperidone—Leukopenia—Capecitabine—breast cancer	3.86e-05	0.000379	CcSEcCtD
Iloperidone—Paraesthesia—Paclitaxel—breast cancer	3.85e-05	0.000378	CcSEcCtD
Iloperidone—Rash—Thiotepa—breast cancer	3.84e-05	0.000377	CcSEcCtD
Iloperidone—Dermatitis—Thiotepa—breast cancer	3.84e-05	0.000377	CcSEcCtD
Iloperidone—Dyspnoea—Paclitaxel—breast cancer	3.82e-05	0.000376	CcSEcCtD
Iloperidone—Somnolence—Paclitaxel—breast cancer	3.81e-05	0.000375	CcSEcCtD
Iloperidone—Palpitations—Capecitabine—breast cancer	3.81e-05	0.000374	CcSEcCtD
Iloperidone—Arthralgia—Docetaxel—breast cancer	3.79e-05	0.000372	CcSEcCtD
Iloperidone—Myalgia—Docetaxel—breast cancer	3.79e-05	0.000372	CcSEcCtD
Iloperidone—Nausea—Vinorelbine—breast cancer	3.79e-05	0.000372	CcSEcCtD
Iloperidone—Asthenia—Mitoxantrone—breast cancer	3.77e-05	0.000371	CcSEcCtD
Iloperidone—Asthenia—Irinotecan—breast cancer	3.77e-05	0.000371	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—breast cancer	3.75e-05	0.000368	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—breast cancer	3.74e-05	0.000367	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—breast cancer	3.73e-05	0.000366	CcSEcCtD
Iloperidone—Dry mouth—Docetaxel—breast cancer	3.71e-05	0.000364	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—breast cancer	3.71e-05	0.000364	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Paclitaxel—breast cancer	3.7e-05	0.000364	CcSEcCtD
Iloperidone—Fatigue—Paclitaxel—breast cancer	3.7e-05	0.000363	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—breast cancer	3.69e-05	0.000362	CcSEcCtD
Iloperidone—Asthenia—Gemcitabine—breast cancer	3.68e-05	0.000361	CcSEcCtD
Iloperidone—Myalgia—Capecitabine—breast cancer	3.67e-05	0.000361	CcSEcCtD
Iloperidone—Arthralgia—Capecitabine—breast cancer	3.67e-05	0.000361	CcSEcCtD
Iloperidone—Confusional state—Docetaxel—breast cancer	3.67e-05	0.00036	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—breast cancer	3.64e-05	0.000358	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—breast cancer	3.64e-05	0.000357	CcSEcCtD
Iloperidone—Oedema—Docetaxel—breast cancer	3.64e-05	0.000357	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—breast cancer	3.63e-05	0.000357	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—breast cancer	3.63e-05	0.000356	CcSEcCtD
Iloperidone—Nausea—Thiotepa—breast cancer	3.62e-05	0.000355	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—breast cancer	3.62e-05	0.000355	CcSEcCtD
Iloperidone—Infection—Docetaxel—breast cancer	3.61e-05	0.000355	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—breast cancer	3.61e-05	0.000355	CcSEcCtD
Iloperidone—Diarrhoea—Irinotecan—breast cancer	3.6e-05	0.000353	CcSEcCtD
Iloperidone—Diarrhoea—Mitoxantrone—breast cancer	3.6e-05	0.000353	CcSEcCtD
Iloperidone—Dry mouth—Capecitabine—breast cancer	3.59e-05	0.000353	CcSEcCtD
Iloperidone—Nervous system disorder—Docetaxel—breast cancer	3.57e-05	0.00035	CcSEcCtD
Iloperidone—Confusional state—Capecitabine—breast cancer	3.55e-05	0.000349	CcSEcCtD
Iloperidone—Tachycardia—Docetaxel—breast cancer	3.55e-05	0.000348	CcSEcCtD
Iloperidone—Feeling abnormal—Paclitaxel—breast cancer	3.54e-05	0.000347	CcSEcCtD
Iloperidone—Oedema—Capecitabine—breast cancer	3.52e-05	0.000346	CcSEcCtD
Iloperidone—Diarrhoea—Gemcitabine—breast cancer	3.51e-05	0.000344	CcSEcCtD
Iloperidone—Infection—Capecitabine—breast cancer	3.5e-05	0.000343	CcSEcCtD
Iloperidone—Dizziness—Irinotecan—breast cancer	3.48e-05	0.000342	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—breast cancer	3.47e-05	0.000341	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—breast cancer	3.46e-05	0.00034	CcSEcCtD
Iloperidone—Nervous system disorder—Capecitabine—breast cancer	3.45e-05	0.000339	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—breast cancer	3.45e-05	0.000339	CcSEcCtD
Iloperidone—Diarrhoea—Fluorouracil—breast cancer	3.45e-05	0.000338	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—breast cancer	3.44e-05	0.000338	CcSEcCtD
Iloperidone—Tachycardia—Capecitabine—breast cancer	3.44e-05	0.000337	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—breast cancer	3.42e-05	0.000336	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—breast cancer	3.41e-05	0.000335	CcSEcCtD
Iloperidone—Hypotension—Docetaxel—breast cancer	3.4e-05	0.000334	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—breast cancer	3.39e-05	0.000333	CcSEcCtD
Iloperidone—Body temperature increased—Paclitaxel—breast cancer	3.39e-05	0.000333	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—breast cancer	3.38e-05	0.000332	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—breast cancer	3.37e-05	0.00033	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—breast cancer	3.36e-05	0.00033	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—breast cancer	3.35e-05	0.000329	CcSEcCtD
Iloperidone—Dizziness—Fluorouracil—breast cancer	3.33e-05	0.000327	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—breast cancer	3.32e-05	0.000326	CcSEcCtD
Iloperidone—Rash—Mitoxantrone—breast cancer	3.32e-05	0.000326	CcSEcCtD
Iloperidone—Rash—Irinotecan—breast cancer	3.32e-05	0.000326	CcSEcCtD
Iloperidone—Dermatitis—Mitoxantrone—breast cancer	3.31e-05	0.000325	CcSEcCtD
Iloperidone—Dermatitis—Irinotecan—breast cancer	3.31e-05	0.000325	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Docetaxel—breast cancer	3.31e-05	0.000325	CcSEcCtD
Iloperidone—Hypotension—Capecitabine—breast cancer	3.29e-05	0.000323	CcSEcCtD
Iloperidone—Paraesthesia—Docetaxel—breast cancer	3.27e-05	0.000321	CcSEcCtD
Iloperidone—Dyspnoea—Docetaxel—breast cancer	3.24e-05	0.000318	CcSEcCtD
Iloperidone—Somnolence—Docetaxel—breast cancer	3.23e-05	0.000317	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—breast cancer	3.23e-05	0.000317	CcSEcCtD
Iloperidone—Rash—Gemcitabine—breast cancer	3.23e-05	0.000317	CcSEcCtD
Iloperidone—Dermatitis—Gemcitabine—breast cancer	3.23e-05	0.000317	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—breast cancer	3.23e-05	0.000317	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—breast cancer	3.22e-05	0.000316	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—breast cancer	3.21e-05	0.000315	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Capecitabine—breast cancer	3.21e-05	0.000315	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—breast cancer	3.2e-05	0.000315	CcSEcCtD
Iloperidone—Rash—Fluorouracil—breast cancer	3.18e-05	0.000312	CcSEcCtD
Iloperidone—Dermatitis—Fluorouracil—breast cancer	3.17e-05	0.000312	CcSEcCtD
Iloperidone—Paraesthesia—Capecitabine—breast cancer	3.16e-05	0.00031	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—breast cancer	3.15e-05	0.00031	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Docetaxel—breast cancer	3.14e-05	0.000308	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—breast cancer	3.14e-05	0.000308	CcSEcCtD
Iloperidone—Dyspnoea—Capecitabine—breast cancer	3.14e-05	0.000308	CcSEcCtD
Iloperidone—Fatigue—Docetaxel—breast cancer	3.13e-05	0.000308	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—breast cancer	3.13e-05	0.000308	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—breast cancer	3.13e-05	0.000307	CcSEcCtD
Iloperidone—Nausea—Irinotecan—breast cancer	3.12e-05	0.000307	CcSEcCtD
Iloperidone—Nausea—Mitoxantrone—breast cancer	3.12e-05	0.000307	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—breast cancer	3.11e-05	0.000306	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—breast cancer	3.08e-05	0.000303	CcSEcCtD
Iloperidone—Asthenia—Paclitaxel—breast cancer	3.08e-05	0.000302	CcSEcCtD
Iloperidone—Nausea—Gemcitabine—breast cancer	3.04e-05	0.000299	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Capecitabine—breast cancer	3.04e-05	0.000298	CcSEcCtD
Iloperidone—Fatigue—Capecitabine—breast cancer	3.04e-05	0.000298	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—breast cancer	3.03e-05	0.000297	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—breast cancer	3.02e-05	0.000297	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—breast cancer	3.01e-05	0.000295	CcSEcCtD
Iloperidone—Feeling abnormal—Docetaxel—breast cancer	3e-05	0.000294	CcSEcCtD
Iloperidone—Nausea—Fluorouracil—breast cancer	2.99e-05	0.000294	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—breast cancer	2.98e-05	0.000293	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—breast cancer	2.98e-05	0.000292	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—breast cancer	2.97e-05	0.000291	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—breast cancer	2.96e-05	0.000291	CcSEcCtD
Iloperidone—Diarrhoea—Paclitaxel—breast cancer	2.94e-05	0.000288	CcSEcCtD
Iloperidone—Feeling abnormal—Capecitabine—breast cancer	2.9e-05	0.000285	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—breast cancer	2.9e-05	0.000285	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—breast cancer	2.89e-05	0.000284	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—breast cancer	2.89e-05	0.000283	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—breast cancer	2.88e-05	0.000283	CcSEcCtD
Iloperidone—Body temperature increased—Docetaxel—breast cancer	2.87e-05	0.000282	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—breast cancer	2.87e-05	0.000282	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—breast cancer	2.85e-05	0.00028	CcSEcCtD
Iloperidone—Dizziness—Paclitaxel—breast cancer	2.84e-05	0.000279	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—breast cancer	2.83e-05	0.000278	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—breast cancer	2.8e-05	0.000275	CcSEcCtD
Iloperidone—Body temperature increased—Capecitabine—breast cancer	2.78e-05	0.000273	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—breast cancer	2.78e-05	0.000273	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—breast cancer	2.78e-05	0.000273	CcSEcCtD
Iloperidone—Agitation—Epirubicin—breast cancer	2.76e-05	0.000271	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—breast cancer	2.73e-05	0.000268	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—breast cancer	2.73e-05	0.000268	CcSEcCtD
Iloperidone—Rash—Paclitaxel—breast cancer	2.7e-05	0.000266	CcSEcCtD
Iloperidone—Dermatitis—Paclitaxel—breast cancer	2.7e-05	0.000265	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—breast cancer	2.7e-05	0.000265	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—breast cancer	2.69e-05	0.000264	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—breast cancer	2.67e-05	0.000263	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—breast cancer	2.66e-05	0.000261	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—breast cancer	2.64e-05	0.000259	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—breast cancer	2.62e-05	0.000257	CcSEcCtD
Iloperidone—Asthenia—Docetaxel—breast cancer	2.61e-05	0.000256	CcSEcCtD
Iloperidone—Infection—Methotrexate—breast cancer	2.6e-05	0.000256	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—breast cancer	2.57e-05	0.000252	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—breast cancer	2.57e-05	0.000252	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—breast cancer	2.56e-05	0.000251	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—breast cancer	2.56e-05	0.000251	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—breast cancer	2.56e-05	0.000251	CcSEcCtD
Iloperidone—Nausea—Paclitaxel—breast cancer	2.55e-05	0.00025	CcSEcCtD
Iloperidone—Asthenia—Capecitabine—breast cancer	2.53e-05	0.000248	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—breast cancer	2.5e-05	0.000246	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—breast cancer	2.5e-05	0.000245	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—breast cancer	2.49e-05	0.000244	CcSEcCtD
Iloperidone—Diarrhoea—Docetaxel—breast cancer	2.49e-05	0.000244	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—breast cancer	2.47e-05	0.000243	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—breast cancer	2.46e-05	0.000241	CcSEcCtD
Iloperidone—Oedema—Epirubicin—breast cancer	2.45e-05	0.000241	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—breast cancer	2.45e-05	0.00024	CcSEcCtD
Iloperidone—Infection—Epirubicin—breast cancer	2.44e-05	0.000239	CcSEcCtD
Iloperidone—Diarrhoea—Capecitabine—breast cancer	2.41e-05	0.000237	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—breast cancer	2.41e-05	0.000236	CcSEcCtD
Iloperidone—Dizziness—Docetaxel—breast cancer	2.4e-05	0.000236	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—breast cancer	2.39e-05	0.000235	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—breast cancer	2.39e-05	0.000234	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—breast cancer	2.37e-05	0.000232	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—breast cancer	2.37e-05	0.000232	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—breast cancer	2.35e-05	0.000231	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—breast cancer	2.34e-05	0.000229	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—breast cancer	2.33e-05	0.000229	CcSEcCtD
Iloperidone—Dizziness—Capecitabine—breast cancer	2.33e-05	0.000229	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—breast cancer	2.32e-05	0.000227	CcSEcCtD
Iloperidone—Rash—Docetaxel—breast cancer	2.29e-05	0.000225	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—breast cancer	2.29e-05	0.000225	CcSEcCtD
Iloperidone—Dermatitis—Docetaxel—breast cancer	2.29e-05	0.000225	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—breast cancer	2.29e-05	0.000225	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—breast cancer	2.27e-05	0.000223	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—breast cancer	2.26e-05	0.000222	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—breast cancer	2.26e-05	0.000222	CcSEcCtD
Iloperidone—Infection—Doxorubicin—breast cancer	2.25e-05	0.000221	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—breast cancer	2.23e-05	0.000219	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—breast cancer	2.23e-05	0.000219	CcSEcCtD
Iloperidone—Rash—Capecitabine—breast cancer	2.22e-05	0.000218	CcSEcCtD
Iloperidone—Dermatitis—Capecitabine—breast cancer	2.22e-05	0.000218	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—breast cancer	2.21e-05	0.000217	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—breast cancer	2.2e-05	0.000216	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—breast cancer	2.19e-05	0.000215	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—breast cancer	2.18e-05	0.000214	CcSEcCtD
Iloperidone—Nausea—Docetaxel—breast cancer	2.16e-05	0.000212	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—breast cancer	2.16e-05	0.000212	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—breast cancer	2.12e-05	0.000208	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—breast cancer	2.12e-05	0.000208	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—breast cancer	2.11e-05	0.000208	CcSEcCtD
Iloperidone—Nausea—Capecitabine—breast cancer	2.09e-05	0.000205	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—breast cancer	2.07e-05	0.000203	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.07e-05	0.000203	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—breast cancer	2.04e-05	0.0002	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—breast cancer	2.02e-05	0.000199	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—breast cancer	2.02e-05	0.000198	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—breast cancer	2.02e-05	0.000198	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—breast cancer	1.96e-05	0.000192	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—breast cancer	1.96e-05	0.000192	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—breast cancer	1.94e-05	0.00019	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—breast cancer	1.88e-05	0.000185	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—breast cancer	1.87e-05	0.000184	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—breast cancer	1.79e-05	0.000176	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—breast cancer	1.79e-05	0.000176	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—breast cancer	1.76e-05	0.000173	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—breast cancer	1.73e-05	0.00017	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—breast cancer	1.68e-05	0.000165	CcSEcCtD
Iloperidone—Rash—Methotrexate—breast cancer	1.65e-05	0.000162	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—breast cancer	1.65e-05	0.000162	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—breast cancer	1.63e-05	0.00016	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—breast cancer	1.62e-05	0.000159	CcSEcCtD
Iloperidone—Nausea—Methotrexate—breast cancer	1.56e-05	0.000153	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—breast cancer	1.55e-05	0.000152	CcSEcCtD
Iloperidone—Rash—Epirubicin—breast cancer	1.55e-05	0.000152	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—breast cancer	1.54e-05	0.000152	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—breast cancer	1.5e-05	0.000147	CcSEcCtD
Iloperidone—Nausea—Epirubicin—breast cancer	1.46e-05	0.000143	CcSEcCtD
Iloperidone—Rash—Doxorubicin—breast cancer	1.43e-05	0.000141	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—breast cancer	1.43e-05	0.00014	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—breast cancer	1.35e-05	0.000132	CcSEcCtD
Iloperidone—HTR1A—Signaling Pathways—SRC—breast cancer	1.02e-06	1.67e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—breast cancer	1.02e-06	1.67e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CG—breast cancer	1.02e-06	1.67e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SRC—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ERBB2—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CASP3—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CASP3—breast cancer	1.01e-06	1.66e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—breast cancer	1.01e-06	1.65e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—breast cancer	1e-06	1.65e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—breast cancer	1e-06	1.65e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—breast cancer	1e-06	1.64e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PIK3CA—breast cancer	1e-06	1.64e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—breast cancer	9.99e-07	1.64e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	9.98e-07	1.64e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MTOR—breast cancer	9.98e-07	1.64e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	9.98e-07	1.64e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—JUN—breast cancer	9.96e-07	1.64e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—breast cancer	9.91e-07	1.63e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CTNNB1—breast cancer	9.89e-07	1.63e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CASP3—breast cancer	9.88e-07	1.62e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—breast cancer	9.87e-07	1.62e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—breast cancer	9.86e-07	1.62e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SRC—breast cancer	9.85e-07	1.62e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—breast cancer	9.83e-07	1.61e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—breast cancer	9.82e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—breast cancer	9.82e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—JUN—breast cancer	9.8e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—breast cancer	9.8e-07	1.61e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—breast cancer	9.8e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—JUN—breast cancer	9.78e-07	1.61e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—COMT—breast cancer	9.78e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—breast cancer	9.77e-07	1.61e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CTNNB1—breast cancer	9.73e-07	1.6e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTP1—breast cancer	9.73e-07	1.6e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CTNNB1—breast cancer	9.71e-07	1.6e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—breast cancer	9.69e-07	1.59e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—breast cancer	9.68e-07	1.59e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—breast cancer	9.68e-07	1.59e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—breast cancer	9.67e-07	1.59e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—breast cancer	9.67e-07	1.59e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CDKN1A—breast cancer	9.66e-07	1.59e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—breast cancer	9.64e-07	1.58e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—breast cancer	9.62e-07	1.58e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—breast cancer	9.61e-07	1.58e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—JUN—breast cancer	9.6e-07	1.58e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—HMOX1—breast cancer	9.6e-07	1.58e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—breast cancer	9.59e-07	1.58e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—breast cancer	9.59e-07	1.58e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ITPR1—breast cancer	9.57e-07	1.57e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—breast cancer	9.54e-07	1.57e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—breast cancer	9.53e-07	1.57e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	9.53e-07	1.57e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—breast cancer	9.52e-07	1.56e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CDKN1A—breast cancer	9.5e-07	1.56e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—breast cancer	9.5e-07	1.56e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CDKN1A—breast cancer	9.48e-07	1.56e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—breast cancer	9.48e-07	1.56e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—breast cancer	9.47e-07	1.56e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—breast cancer	9.46e-07	1.56e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—breast cancer	9.46e-07	1.55e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CAV1—breast cancer	9.44e-07	1.55e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK8—breast cancer	9.43e-07	1.55e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—breast cancer	9.4e-07	1.55e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK3—breast cancer	9.38e-07	1.54e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	9.37e-07	1.54e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—breast cancer	9.34e-07	1.54e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK3—breast cancer	9.33e-07	1.53e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	9.31e-07	1.53e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—breast cancer	9.29e-07	1.53e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK8—breast cancer	9.28e-07	1.52e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	9.27e-07	1.52e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—breast cancer	9.26e-07	1.52e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK8—breast cancer	9.26e-07	1.52e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—breast cancer	9.26e-07	1.52e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—breast cancer	9.25e-07	1.52e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—breast cancer	9.25e-07	1.52e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—breast cancer	9.23e-07	1.52e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PIK3CA—breast cancer	9.23e-07	1.52e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ABCB1—breast cancer	9.21e-07	1.51e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—breast cancer	9.19e-07	1.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CASP3—breast cancer	9.18e-07	1.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—breast cancer	9.17e-07	1.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—breast cancer	9.12e-07	1.5e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—breast cancer	9.12e-07	1.5e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFB1—breast cancer	9.1e-07	1.5e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK8—breast cancer	9.08e-07	1.49e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK3—breast cancer	9.08e-07	1.49e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—breast cancer	9.08e-07	1.49e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—breast cancer	9.06e-07	1.49e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFB1—breast cancer	9.05e-07	1.49e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—TYMS—breast cancer	9.05e-07	1.49e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	9.02e-07	1.48e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PIK3CA—breast cancer	9.01e-07	1.48e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PIK3CA—breast cancer	8.96e-07	1.47e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NCOR1—breast cancer	8.94e-07	1.47e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PLA2G4A—breast cancer	8.94e-07	1.47e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTM1—breast cancer	8.94e-07	1.47e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—breast cancer	8.94e-07	1.47e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SRC—breast cancer	8.94e-07	1.47e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CD—breast cancer	8.93e-07	1.47e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EGFR—breast cancer	8.92e-07	1.47e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—JUN—breast cancer	8.92e-07	1.47e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PIK3CA—breast cancer	8.89e-07	1.46e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EGFR—breast cancer	8.88e-07	1.46e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—breast cancer	8.86e-07	1.46e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	8.85e-07	1.45e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—breast cancer	8.83e-07	1.45e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ALB—breast cancer	8.81e-07	1.45e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFB1—breast cancer	8.81e-07	1.45e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SRC—breast cancer	8.79e-07	1.45e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SRC—breast cancer	8.78e-07	1.44e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—breast cancer	8.71e-07	1.43e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—breast cancer	8.71e-07	1.43e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—breast cancer	8.68e-07	1.43e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	8.65e-07	1.42e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EGFR—breast cancer	8.63e-07	1.42e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—breast cancer	8.63e-07	1.42e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—breast cancer	8.62e-07	1.42e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SRC—breast cancer	8.61e-07	1.42e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CG—breast cancer	8.6e-07	1.41e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—breast cancer	8.6e-07	1.41e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—breast cancer	8.57e-07	1.41e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GPX1—breast cancer	8.56e-07	1.41e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—breast cancer	8.55e-07	1.4e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—breast cancer	8.55e-07	1.4e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—breast cancer	8.54e-07	1.4e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—breast cancer	8.48e-07	1.39e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—breast cancer	8.48e-07	1.39e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CYP1A1—breast cancer	8.48e-07	1.39e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—breast cancer	8.46e-07	1.39e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK8—breast cancer	8.44e-07	1.39e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—NOS3—breast cancer	8.43e-07	1.39e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—breast cancer	8.43e-07	1.39e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—breast cancer	8.42e-07	1.38e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ERCC2—breast cancer	8.41e-07	1.38e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—breast cancer	8.39e-07	1.38e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—breast cancer	8.39e-07	1.38e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—breast cancer	8.33e-07	1.37e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—breast cancer	8.3e-07	1.37e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK3—breast cancer	8.24e-07	1.35e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—breast cancer	8.22e-07	1.35e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—breast cancer	8.17e-07	1.34e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—breast cancer	8.16e-07	1.34e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK3—breast cancer	8.1e-07	1.33e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK3—breast cancer	8.09e-07	1.33e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—breast cancer	8.01e-07	1.32e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SRC—breast cancer	8e-07	1.32e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFB1—breast cancer	7.99e-07	1.31e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—breast cancer	7.97e-07	1.31e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK3—breast cancer	7.93e-07	1.3e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—MTHFR—breast cancer	7.9e-07	1.3e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—breast cancer	7.88e-07	1.3e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—breast cancer	7.87e-07	1.29e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—breast cancer	7.86e-07	1.29e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFB1—breast cancer	7.86e-07	1.29e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFB1—breast cancer	7.84e-07	1.29e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EGFR—breast cancer	7.83e-07	1.29e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—breast cancer	7.79e-07	1.28e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CB—breast cancer	7.78e-07	1.28e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PIK3CA—breast cancer	7.74e-07	1.27e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—breast cancer	7.72e-07	1.27e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—breast cancer	7.72e-07	1.27e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—breast cancer	7.71e-07	1.27e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EGFR—breast cancer	7.71e-07	1.27e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PIK3CA—breast cancer	7.7e-07	1.27e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFB1—breast cancer	7.7e-07	1.27e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EGFR—breast cancer	7.69e-07	1.26e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CD—breast cancer	7.56e-07	1.24e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EGFR—breast cancer	7.55e-07	1.24e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—breast cancer	7.54e-07	1.24e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	7.49e-07	1.23e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—breast cancer	7.49e-07	1.23e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ALB—breast cancer	7.47e-07	1.23e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—breast cancer	7.45e-07	1.23e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—breast cancer	7.4e-07	1.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK3—breast cancer	7.37e-07	1.21e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—breast cancer	7.36e-07	1.21e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—breast cancer	7.32e-07	1.2e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CAV1—breast cancer	7.29e-07	1.2e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—breast cancer	7.28e-07	1.2e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PIK3CA—breast cancer	7.28e-07	1.2e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—breast cancer	7.27e-07	1.19e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—breast cancer	7.26e-07	1.19e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—breast cancer	7.25e-07	1.19e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—breast cancer	7.17e-07	1.18e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—breast cancer	7.16e-07	1.18e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFB1—breast cancer	7.15e-07	1.18e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—NOS3—breast cancer	7.14e-07	1.17e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—breast cancer	7.13e-07	1.17e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—breast cancer	7.13e-07	1.17e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EGFR—breast cancer	7.01e-07	1.15e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—breast cancer	6.93e-07	1.14e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—breast cancer	6.86e-07	1.13e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—breast cancer	6.82e-07	1.12e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CA—breast cancer	6.8e-07	1.12e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—breast cancer	6.72e-07	1.11e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CA—breast cancer	6.69e-07	1.1e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CA—breast cancer	6.68e-07	1.1e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CA—breast cancer	6.68e-07	1.1e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CA—breast cancer	6.67e-07	1.1e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CG—breast cancer	6.64e-07	1.09e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—breast cancer	6.64e-07	1.09e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—breast cancer	6.62e-07	1.09e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CB—breast cancer	6.59e-07	1.08e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—breast cancer	6.58e-07	1.08e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	6.55e-07	1.08e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—breast cancer	6.53e-07	1.07e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—breast cancer	6.47e-07	1.06e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—breast cancer	6.46e-07	1.06e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—breast cancer	6.34e-07	1.04e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—breast cancer	6.33e-07	1.04e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—breast cancer	6.29e-07	1.03e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—breast cancer	6.29e-07	1.03e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—breast cancer	6.19e-07	1.02e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—breast cancer	6.18e-07	1.02e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—breast cancer	6.12e-07	1.01e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	6.09e-07	1e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—breast cancer	6.06e-07	9.96e-06	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—breast cancer	6.02e-07	9.9e-06	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—breast cancer	5.95e-07	9.77e-06	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—breast cancer	5.92e-07	9.74e-06	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—breast cancer	5.91e-07	9.72e-06	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—breast cancer	5.89e-07	9.68e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CD—breast cancer	5.84e-07	9.59e-06	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—breast cancer	5.8e-07	9.53e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ALB—breast cancer	5.76e-07	9.47e-06	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—breast cancer	5.7e-07	9.36e-06	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—breast cancer	5.63e-07	9.26e-06	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—breast cancer	5.55e-07	9.13e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NOS3—breast cancer	5.51e-07	9.06e-06	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—breast cancer	5.47e-07	8.98e-06	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—breast cancer	5.46e-07	8.98e-06	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—breast cancer	5.45e-07	8.96e-06	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—breast cancer	5.45e-07	8.96e-06	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—breast cancer	5.39e-07	8.86e-06	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—breast cancer	5.35e-07	8.8e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CB—breast cancer	5.09e-07	8.36e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—breast cancer	5.04e-07	8.29e-06	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—breast cancer	4.97e-07	8.17e-06	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CA—breast cancer	4.74e-07	7.8e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—breast cancer	4.4e-07	7.23e-06	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CA—breast cancer	4.02e-07	6.6e-06	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—breast cancer	3.87e-07	6.37e-06	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—breast cancer	3.28e-07	5.4e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CA—breast cancer	3.1e-07	5.1e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—breast cancer	2.53e-07	4.16e-06	CbGpPWpGaD
